Ts role in malignant hematologic problems.AcknowledgmentsThis operate was supported by the National Natural Science Foundation of China (81274142, 30300139), and also the Natural Science Foundation of Science and Technologies Commission of Shanghai Municipality (11ZR1423400) and theDrug Design, Improvement and Therapy 2015:DovepressDovepressas4s4 combined therapy in gastric and colon cancer 21. Lal G, Ash C, Hay K, et al. Suppression of intestinal polyps in Msh2deficient and non-Msh2-deficient a number of intestinal neoplasia mice by a specific cyclooxygenase-2 GLYX-13 Protocol inhibitor and by a dual cyclooxygenase-1/2 inhibitor. Cancer Res. 2001;61(16):6131?136. 22. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical concerns. J Natl Cancer Inst. 2002;94(four):252?66. 23. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered in the course of different stages of carcinogenesis. Cancer Res. 2000;60(two):293?97. 24. Koki AT, Masferrer JL. Celecoxib: a precise COX-2 inhibitor with anticancer properties. Cancer Manage. 2002;9(two Suppl):28?5. 25. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342(26):1946?952. 26. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9): 873?84. 27. Agrawal A, Fentiman IS. NSAIDs and breast cancer: a achievable prevention and treatment method. Int J Clin Pract. 2008;62(3):444?49. 28. Printz C. Celecoxib could avoid lung cancer. Cancer. 2012;118(1):3. 29. Qiu H, Jackson AL, Kilgore JE, et al. JQ1 suppresses tumor development by way of downregulating LDHA in ovarian cancer. Oncotarget. 2015;6(9):6915?930. 30. Li Z, Wu C, Wu J, et al. Synergistic antitumor effects of combined deguelin and cisplatin therapy in gastric cancer cells. Oncol Lett. 2014;8(four):1603?607. 31. Yuan TM, Liang RY, Chueh PJ, Chuang SM. Role of ribophorin II inside the response to anticancer drugs in gastric cancer cell lines. Oncol Lett. 2015;9(four):1861?868. 32. Kim J, Kim N, Park JH, et al. The Impact of Helicobacter pylori on Epidermal Growth Aspect Receptor Induced Signal Transduction along with the Preventive Impact of Celecoxib in Gastric Cancer Cells. Gut Liver. 2013;7(five):552?59. 33. Wang H, Ke F, Zheng J. Hedgehog-glioma-associated oncogene homolog-1 signaling in colon cancer cells and its role in the celecoxibmediated anti-cancer effect. Oncol Lett. 2014;8(5):2203?208. 34. Cunningham D, 1-Dodecylimidazole Fungal Starling N, Rao S, et al. Capecitabine and oxaliplatin for sophisticated esophagogastric cancer. N Engl J Med. 2008;358(1):36?6. 35. Zaniboni A, Barni S, Labianca R, et al. Epirubicin, cisplatin, and continuous infusion 5-fluorouracil is an active and secure regimen for patients with advanced gastric cancer. An Italian Group for the Study of Digestive Tract Cancer (GISCAD) report. Cancer. 1995;76(10):1694?699. 36. Guimbaud R, Louvet C, Ries P, et al. Prospective, randomized, multicenter, phase III study of fluorouracil, leucovorin, and irinotecan versus epirubicin, cisplatin, and capecitabine in advanced gastric adenocarcinoma: a French intergroup (F ation Francophone de Canc ologie Digestive, F ation Nationale des Centres de Lutte Contre le Cancer, and Groupe Coop ateur Multidisciplinaire en Oncologie) study. J Clin Oncol. 2014;32(31):3520?526. 37. Conroy T, Desseigne F, Ychou M, et al.